Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +42

Boston Scientific Corporation $BSX Shares Sold by Bleakley Financial ...

AI-generated analysis

πŸ“‰ Bleakley Financial Group LLC cut its stake in Boston Scientific by 51.3% in Q1, reducing holdings from roughly 89,693 shares to 43,694 shares.

πŸ“ˆ Ieq Capital LLC significantly increased its position by 97.0% in Q2, acquiring an additional 60,860 shares valued at $13.275 million.

πŸ’° Boston Scientific reported Q1 revenue of $5.20 billion, beating the consensus estimate of $5.19 billion by $11 million.

πŸ“Š The company posted earnings per share of $0.80, surpassing analyst expectations of $0.79 for the quarter.

πŸš€ Revenue grew 11.6% year-over-year, demonstrating continued top-line expansion in the medical device sector.

πŸ’΅ The business maintained a healthy net margin of 17.29% and a return on equity of 19.17%.

πŸ”„ Management authorized a new $5.00 billion stock buyback program, allowing repurchase of up to 6.4% of outstanding shares.

πŸ“… Q2 2026 EPS guidance is set between $0.820 and $0.840, with full-year FY 2026 guidance at $3.340-$3.410.

πŸ‘” Insider buying activity was notable in May, with directors Ludwig and Habiger purchasing shares totaling over $328,000.

πŸ“‰ Analyst sentiment is mixed; Wells Fargo lowered its target to $55 while Goldman Sachs maintains a $71 target.

βš–οΈ Weiss Ratings downgraded the stock to a 'sell' rating, contrasting with a majority of analysts who hold 'buy' ratings.

🏒 Institutional ownership stands at 89.07%, indicating strong interest from major investment firms.

Bullish Signals
  • Boston Scientific beat Q1 earnings estimates with $0.80 EPS versus the consensus of $0.79, signaling operational strength.
  • Revenue increased by 11.6% year-over-year to reach $5.20 billion, exceeding analyst expectations of $5.19 billion.
  • The company secured a new $5.00 billion stock buyback authorization, suggesting management confidence in share value.
  • Ieq Capital LLC aggressively increased its stake by 97.0% in Q2, adding over 60,000 shares to its portfolio.
  • Insider buying was robust in May, with directors purchasing $554,012 worth of stock over the last ninety days.
  • The company maintains a strong net margin of 17.29% and a return on equity of 19.17%.
Risk Factors
  • Wells Fargo & Company lowered its price target to $55.00 from $75.00, citing potential valuation concerns.
  • Barclays reduced its price target from $96.00 to $89.00 while maintaining an overweight rating.
  • Weiss Ratings downgraded the stock from a 'hold' to a 'sell' rating in early July.
  • Analyst consensus targets vary widely, with some firms like Piper Sandler at $65.00 and Goldman Sachs at $71.00.
Full Analysis
Institutional investors have made mixed moves regarding Boston Scientific Corporation (NYSE:BSX) in recent quarters. Bleakley Financial Group LLC significantly reduced its stake by 51.3% in the first quarter, selling over 45,000 shares. Conversely, several other funds increased their positions; Ieq Capital LLC raised holdings by 97.0%, Main Street Financial Solutions by 35.3%, and HUB Investment Partners by 56.2%. Insider activity remains positive, with directors Edward J. Ludwig and David C. Habiger purchasing shares in May, bringing total insider ownership to 0.34%. Financially, Boston Scientific reported strong Q1 results on April 22nd, beating earnings estimates of $0.79 with actual EPS of $0.80 and revenue of $5.20 billion against a consensus of $5.19 billion. The company achieved an 11.6% year-over-year revenue increase, maintaining a net margin of 17.29% and a return on equity of 19.17%. Looking ahead, the company has provided Q2 2026 guidance for EPS between $0.820 and $0.840, with full-year FY 2026 guidance ranging from $3.340 to $3.410. The company announced a new stock buyback plan authorized on May 18th, permitting the repurchase of up to $5.00 billion in outstanding shares, which represents approximately 6.4% of its total share count. Analyst sentiment is mixed but generally leans positive with a consensus target price of $79.92. While some firms like Barclays and Goldman Sachs maintain overweight ratings with targets near $89-$71, others including Wells Fargo lowered targets to $55, and Weiss Ratings issued a sell rating.